[New cytostatic drugs. Status: 1986].
In oncology phase-II studies are planned for testing antitumor activity in a series of malignant tumors. Most important is the development of drugs from entirely new classes of chemicals, fermentation products etc. Clinical research with analogues of known cytotoxic drugs aims at broader spectra of activity and at decreased toxicity in an attempt to avoid, for example, the cardiac toxicity of the anthracyclines or the renal and gastrointestinal toxicities of cis-platinum.
Gallmeier
W M
WM
5. Medizinische Klinik und Institut für Medizinische Onkologie und Hämatologie, Klinikum der Stadt Nürnberg.
Bruntsch
U
U
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D009279:Naphthacenes / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D009279:Naphthacenes; D009607:Nitrosourea Compounds; D002945:Cisplatin
Neue Zytostatika. Stand: 1986.